Governing biological material at the intersection of care and research: the use of dried blood spots for biobanking by Douglas, C.M.W. et al.
390
www.cmj.hr
Governing biological material 
at the intersection of care and 
research: the use of dried blood 
spots for biobanking
Conor M.W. Douglas1, Carla G. van El1, Alex 
Faulkner2, Martina C. Cornel1
1VU University Medical Center Amsterdam, EMGO Institute 
for Health and Care Research, Section Community Genetics, 
Amsterdam, the Netherlands
cm.douglas@vumc.nl
2King’s College London, Department of Political Economy, 
London, United Kingdom
Abstract A series of governance issues currently surrounds 
the multiple uses and multiple users of dried blood spots 
(DBS) for research purposes. Internationally there is a discus-
sion on storing DBS resulting from newborn screening for 
public health and using them as the basis for large biobank-
like collections to facilitate biomedical research. If such a 
transformation were to be formalized, then DBS would sit 
at the intersection of care (ie, public health) and research, 
with the mechanisms through which such a collection 
could be managed not totally self-evident. What is more, a 
DBS collection raises questions about the fuzzy boundaries 
between privacy and anonymity; how to control or define 
quality control uses of DBS; medical vs nonmedical uses; as 
well as benefit sharing and stakeholder involvement. Our 
goal here is to explore some of the key questions relating to 
DBS governance by way of the bio-objects and bio-objec-
tification concepts. By embracing – rather than resisting to 
– the blurring of boundaries and problems in categorization 
that have come to characterize bio-objects and bio-objec-
tification processes recently described in this journal, we at-
tempt to highlight some issues that might not be currently 
considered, and to point to some possible directions to go 
(or avoid). Building from our knowledge of the current DBS 
situation in the Netherlands, we outline questions concern-
ing the uses, management, collection, and storage of DBS.
Establishing and maintaining firm boundaries in biomedi-
cal practices are crucially important activities for establish-
ing legal rights and responsibilities, as well as the naviga-
tion of routes to regulatory approval of new medicines 
and products. Classifications delineate what is and is not 
acceptable within biomedicine, which has knock-on ef-
fects in terms of how science, health care, and bio-
medical research will be structured, organized and funded. 
However, when such boundaries are breached and classi-
fications begin to breakdown, questions are raised about 
how biomedicine will be governed.
For instance, an international discussion is currently tak-
ing place on storing dried blood spots (DBS) resulting from 
newborn screening for public health and using them as the 
basis for large biobank-like collections to facilitate biomedi-
cal research (1-3). In some countries, moving these biologi-
cal materials from the realm of public health screening to 
that of research has led to public outcry on storage of tissues 
without proper consent (4-6). As a result processes are under 
way for considering the reorganization of the procedures for 
collecting, storing, and using DBS. The goal is to balance 
public concerns over stored residual material and to provide 
proper consent vis-ŕ-vis the potential of this kind of biobank-
ing initiative (7). Due to the fact that DBS sit at the intersec-
tion of care (ie, public health) and research, the mechanisms 
through which such a collection could be managed are not 
self-evident. For instance, would these kinds of biological 
materials be open to any kind of research by any interested 
party because of their status of residual – or “left-over” – tis-
sue; or would they be subject to scientific and ethical review 
and on-going informed consent that has to typify biomedi-
cal research and development? A formalized DBS collection 
raises other questions about the fuzzy boundaries between 
privacy and anonymity – how to control or define quality 
control uses of DBS; medical vs nonmedical uses; benefit 
sharing, and stakeholder involvement.
Recently this journal has dedicated space for reflection on 
how novel biological entities – such as a DBS biobank dis-
cussed here – are actively challenging conventional cate-
gorizations, classifications, and boundaries in biomedicine. 
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Such entities – or “bio-objects” – have been described as 
“the products of various efforts to know and enhance (hu-
man) life – that is bio(s) –, through intervening in and ob-
jectifying it, that is through creating often very tangible ob-
jects that can be leveraged and stored, as well as circulated 
and exchanged” (8). Examples of bio-objects are things like 
frozen gametes that raise questions about the living and 
non-living categorizations, because they are simultaneously 
inanimate and the source of vitality (9); microRNA that chal-
lenges the boundary between human and non-humans as 
it migrates from plants to regulate mammalian genes (10), 
or as in the case presented here DBS biobank that contests 
the classifications of health research and health care.
In the face of difficulties to classify these biological forms, 
key governance questions can arise such as: “how to order 
these entities, who to entrust with their oversight, and in 
light of what sort of principles?” (11) Our goal here is to 
explore some of the key questions relating to DBS gover-
nance by way of the bio-objects and bio-objectification 
concepts. By embracing – rather than resisting to – the 
blurring of boundaries, and problems in categorization, we 
attempt to highlight some issues that might not be cur-
rently considered, and to point to some possible directions 
to go (or avoid) for the governance of DBS biobanks.
While the article is grounded in our knowledge of the cur-
rent situation regarding DBS storage, management, and 
use in the Netherlands that we outline in the next section; 
many of the questions pertaining to their governance are 
relevant to similar initiatives taking place around the world. 
With this overview in place, the core of the article is built 
around three themed sections that outline questions con-
cerning (a) the uses of DBS, (b) the management of the 
DBS, and (c) their collection and storage. In our discussion 
section, we suggest that the governance challenges result-
ing from the blurring of research and care in DBS biobank-
ing are connected to other boundary issues pertaining to 
commercial (ie, “private”) and non-commercial (ie, “public”) 
research, as well as to the use of DBS for quality control of 
the screening program vis-ŕ-vis their use in biomedical re-
search and development.
CURRENT SITUATION CONCERNING DBS IN THE 
NETHERLANDS
In the Netherlands, DBS are collected for neo-natal screen-
ing purposes since 1974. Currently, the collection proce-
dure normally takes place as soon as possible after 96 hours 
of age, and is usually combined with the neonatal hearing 
screening. A few drops of blood are collected on filter paper 
and then sent to one of five regional screening laboratories 
where they are screened for a series of seventeen treatable, 
developmental disorders like congenital hypothyroidism, 
metabolic disorders like phenylketonuria, sickle cell disease, 
and as of May 2011 cystic fibrosis. Since 2002, all Dutch 
DBS cards are stored for one-year for quality control at one 
of the regional screening laboratories. With the primary 
screening purpose of the DBS achieved, the residual tissue 
is then moved to the Center for Population Screening (CPS) 
at the National Institute for Public Health and the Environ-
ment (RIVM), where they can be used for confirming diag-
noses, and sometimes for limited scientific research such as 
disease prevalence studies. At the moment of screening, 
parents can indicate if they object to further storage for an-
other four years for research purposes, by ticking an opt-out 
box on the DBS card itself. Currently in the Netherlands, all 
cards are destroyed after this total of five years.
While the collection, storage, and use procedure had been 
stable for the first decades, retention of DBS was publicly 
questioned in 2000 after a fireworks disaster, when it was 
suggested that the cards containing the biological sam-
ples could be used for forensic identification of the victims. 
The main points of contention were that it was not well 
known to parents that DBS cards of their children had been 
stored, and that no consent had been asked for storage. 
It was at that time that the five year retention period and 
consent procedure for research were established.
However, since at least 2005 stakeholders in the Netherlands 
have been discussing secondary use, geneticists have sug-
gested storing a sample of cards for one or more generations 
(30 years) to monitor trends in allele frequencies (12). Any 
changes to the current five-year retention period or to the 
use of DBS would require action by the Programme Com-
mittee Neonatal Heelprick Screening of CPS, which current-
ly advises on policy issues and further development of the 
screening program. It unites stakeholders that include the 
patient organizations (VSOP – Dutch Parents and Patients 
Organisation of Genetic Support Groups), medical doctors 
(eg, metabolic pediatricians), endocrine pediatric experts, 
obstetricians and clinical geneticists, laboratory officials and 
members of the Dutch Forum for Biotechnology and Genet-
ics (FBG), a “think-tank” advising the Ministry of Health, Wel-
fare, and Sports. Any request for secondary use is dealt by 
this Programme Committee Neonatal Heelprick Screening. 
Until now, requests were mainly made for epidemiological 
studies and for development of new screening tests. In 
the literature, suggestions have been made to use the 
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cards for identification and etiological and genome-wide as-
sociation studies (13). As it has been advised to use existing 
collections of biological materials in research, setting up a 
de novo DBS biobank alongside new policies for collection, 
storage, management, and use could work to avoid legal 
problems relating to a lack of consent for prolonged storage 
of the existing DBS samples (14). In the Netherlands, a new 
law on residual body material (Wet Zeggenschap Lichaams-
materiaal) has been drafted, and meanwhile a code of con-
duct has been established. A report from the Dutch science 
and technology policy body – the Rathenau Institute – in 
2009 suggested that under certain conditions many people 
were in favor of doing research on residual material (15). In 
2010, Forum FBG contacted the CPS Programme Commit-
tee Neonatal Heelprick Screening as to whether prolonged 
storage would be possible (16). This was discussed with the 
Ministry of Health, Welfare, and Sport and the CPS was ad-
vised to further study the prolonged storage, secondary 
use, and governance. The Ministry was of the opinion that 
in potential future scenarios, DBS might best be stored with 
a non-governmental body or trusted third party (17). As a 
backdrop to all these discussions, the question remains if 
the costs and risks to the screening program outweigh the 
prospective benefits for serving this extension to the re-
search community?
If such a move to prolong the storage and extend the 
research uses of DBS would be realized, then the public 
health status of this biological material would begin to blur 
into the realm of research and development. Such a blur-
ring would not be without its repercussions for the screen-
ers, the organizers of a DBS biobank, and most importantly 
for parents and the children whose blood is being stored 
and used. The remainder of this article explores some of 
the governance questions that arise when considerations 
are given to this kind of transformative proposal.
THE USE OF DBS IN RESEARCH
To begin, it is important to differentiate between medi-
cal and non-medical uses of DBS. Within the realm of bio-
medicine, we might try to distinguish between use of DBS 
for quality control/assurance or for purposes related to the 
screening program on the one hand, and for research and 
development on the other. The former use is typically as-
sociated with the Center for Population Screening in the 
RIVM, and the latter is open to actors in the biomedical 
domain with ethical and scientific approval. As a result 
it is likely that RIVM wants to keep a firm boundary be-
tween the use of cards for research and the use of 
cards for purposes related to the screening program. This is 
underlined by the fact that parents do not give permission 
for, nor are given the option to opt-out of quality control. 
Therefore, giving consent for screening is giving consent for 
quality control, as quality control can be seen as an essen-
tial part of the screening program. However, it can be de-
bated whether research to optimize the current screening 
can always be clearly distinguished from research toward 
new screens? The example of tandem mass spectrometry 
illustrates how a technology can be used to improve exist-
ing tests, and at the same time open up many new possi-
bilities relating to research and extended screening.
While these differentiations in uses stand to be important for 
the governance of a DBS collection, it may not be advisable 
to create a priori categories for kinds of research that are or 
are not permissible. This is in part due to fuzzy line between 
quality control and research, but it is also increasingly diffi-
cult to differentiate between fundamental research and its 
translation into clinical or commercial implications (eg, dis-
eases prevalence or epidemiology studies being translated 
into research toward development of a new screen).
What is crucial to stress is that certain kinds of research can 
only – or much more readily and reliably – be done with 
DBS (see list below). These uses of DBS should be priori-
tized over other research uses, which may be possible us-
ing other research-specific collections.
• Implementation studies of potential new screening tech-
niques (eg, assays for Pompe disease);
• specific clinical epidemiological studies in which DBS 
from children with specific health problems are studied for 
potential perinatal causal factors (eg, CMV infections in in-
fants with hearing loss);
• prevalence studies (eg, medium chain acyl coenzyme A 
dehydrogenase deficiency in newborns).
The priority and acceptability of other purposes still needs 
to be discussed, eg:
• association studies combining clinical data with DBS 
(Scandinavian countries);
• identification of victims (eg, Enschede fireworks disaster);
• identification for other forensic purposes.
Under what conditions could DBS be used for particular 
kinds of research?
While it is important to keep in mind that biological ma-
terial containing DNA can never truly be anonymous (18), 
the use of DBS de-linked from personal health information 
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is less problematic in terms of privacy and public opinion. 
There are various kinds of linkages between biological in-
formation and data that can take various forms. These are 
summarized in Health Canada Guidance document (19).
It is not self-evident that the future use of DBS for research 
would be linked to any personal information. This is particu-
larly true given the lack of electronic patient records such as 
in the Netherlands. It is likely that the information available 
to link to the DBS would differ during the quality assurance 
period vs the research retention period. For instance, during 
the quality assurance period identifiers such as names and 
contact information must be connected to the DBS for uses 
such as confirming diagnosis or false positives. In the Neth-
erlands, after this quality assurance period – which current-
ly stands at 1 year – DBS are separated from identifiers.
If requests are made for non-anonymous use it should be 
shown that samples could not be accessed from other col-
lections; capitalizing on pre-existing biobanks created for 
research-specific uses should be encouraged. It is the am-
bition that formalizing the DBS collection would entail the 
creation of a research biobank that is representative of all 
newborns. That said, the specific value of a collection rep-
resentative of all newborns with limited associated data 
should be weighed against a large but not comprehensive 
collection with considerable data such as Generation R (ie, 
a prospective cohort study from fetal life until young adult-
hood, based in Rotterdam) (20). With that in mind if [further] 
personal information is desired along with DBS, then per-
mission/informed consent to research participation should 
be obtained at the time of re-contact for personal informa-
tion. Nowadays re-contact starts from clinicians or clinical re-
searchers asking parents for consent for a study requiring the 
DBS of their child. However, this implies linkages between 
the DBS and – at the very least – personal contact informa-
tion during the period in which DBS are retained for research. 
How re-contacting would be practicably done from another 
way around (ie, the DBS collection to parents) is unclear. It 
should be stressed that these conditions are likely to be a 
decision that should be made by a new governance mecha-
nism in the event that the DBS collection is formalized.
Who could use the cards for research?
In the same way that the specific research uses a DBS 
biobank, it facilitates biobank’s needs to be in foreground 
in a discussion on governance. A DBS collection with pro-
longed retention period would attract researchers inter-
ested in effects that go beyond a 5-year cohort. Further, a 
formalized DBS collection with improved storage facilities 
including cold storage (eg, minimum -20°C- and preferable 
-80) would likely serve research related to metabolites (21).
Despite its promise, making decisions about who could use 
the DBS cards is complicated by the dynamics of contem-
porary research, which can be conducted by university re-
searchers yet funded –in full or in part – by the commercial 
sector. Further, contemporary research can also be conduct-
ed by public-private-partnerships; and basic research could 
be done by public institutions, then commercialized by pri-
vate actors (perhaps via a university industrial liaison office, 
the creation of a spin-off, etc). One possible resolution to 
these dynamics and translational mechanisms might be 
the development of clear benefit sharing agreements (eg, 
free licensing) resulting from commercialization.
Irrespective of who are the users, the location of research 
would need to be included in the application to use DBS for 
research, and made explicit in the material transfer agree-
ment. The dynamics of international research, public-pri-
vate research, and translational science, mentioned above 
also apply here as well. Scientific practice is now rarely ho-
mogenous and/or contained. This needs to be recognized 
and integrated into governance mechanisms.
What are the challenges associated with the use of DBS 
and genomic technologies?
New technologies such as genome-wide scans, next gener-
ation sequencing, and epi-genomics offer new potentialities 
for the use of DBS in research. These new uses of DBS may 
pose new questions and raise particular issues. For instance, 
one-off “informed consent” at time of collection (or even 
with re-consenting at 18) may be implausible to provide if 
new technologies open new and unknowable research pos-
sibilities. New technologies, such as whole-genome scans, 
may produce clinically relevant and actionable results. How 
these results are dealt with, and/or returned to the individ-
ual associated with the DBS, needs to be considered. This is 
something biobanks in general are dealing with, but poses 
particular challenges in case of a population-based second-
ary-use biobank, such as in case of the DBS (22). This dynam-
ic of technologies opening research avenues – and concur-
rent issues – is likely to increase in the future.
THE MANAGEMENT AND INSTITUTIONS
Currently in the Netherlands, the Programme Com-
mittee Neonatal Heelprick Screening is responsible 
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for directing the day-to-day newborn screening activities 
and handling requests for the use of DBS for research pur-
poses. This Programme Committee is not solely made-up 
of employees of the screening laboratory and the region-
al screening organization; it also includes representatives 
from other relevant stakeholders, as we discussed before. 
Both Ethical Review Boards and Scientific Advisory Boards 
are already present in most Dutch University Medical Cen-
ters, which would both need to be consulted before a re-
quest is made to the Programme Committee for the use of 
DBS in research.
One institutional mechanism that does not currently exist 
in the Netherlands is a version of the Community Values 
Advisory Board (CVAB) that is currently in place in the state 
of Michigan’s DBS BioTrust (information was provided to us 
via email by Carrie Langbo – the BioTrust Outreach Coordi-
nator – on March 30, 2012). The CVAB is a board of fifteen to 
nineteen members selected to reflect geographic diversity 
and a variety of organizational affiliations and stakeholders 
that include the general public; cultural, religious or his-
torical groups; health professionals; and disease or health 
advocacy organizations. The CVAB is one of three boards 
overseeing the use of DBS for research for the Michigan 
Department of Community Health (MDCH). The other two 
are a Scientific Advisory Board and an Institutional Review 
Board. The CVAB is to play an ongoing role in monitoring 
the ways in which bloodspots are acquired and used for 
research; develop a plan for ongoing community aware-
ness, education, and engagement to inform development, 
review, and revision of BioTrust policies (ie, articulation of 
recommended formats and vehicles for education and en-
gagement for expectant and new parents, and education 
and engagement for the community at large); to develop 
requirements for reports or products that MDCH and/or 
the BioTrust should provide to the CVAB and to the pub-
lic at large; as well as mechanisms for the CVAB to provide 
feedback to MDCH. In particular, emphasis is on advising 
MDCH on how best to continue educating the community 
regarding the existence of the BioTrust, use of dried blood 
spot samples in health research, and individual options for 
participation or non-participation.
What role can – or could – parents and other diverse 
interests play in these institutional mechanisms?
In theory, there would be room for a parent representa-
tive on a Scientific Advisory Board, an Institutional Review 
Board, and an Ethical Review Board. Currently the Dutch 
Programme Committee Neonatal Heelprick Screen-
ing includes patient representatives and in theory there 
would be room for a parent representative as well. While 
possible, it is unknown if there currently are parent repre-
sentatives that sit on these councils or boards – including 
Community Values Advisory Board in Michigan.
An interesting option for the transparent and socially re-
sponsible governance of a DBS collection might be found 
in an “adaptive governance” model proposed by O’Doherty 
et al in their work on population-scale biobanks in Cana-
da, where they refer to representation of participants (23). 
While full description of these mechanisms can be taken 
from the original it is worthwhile noting that the Partici-
pant Association should include all biobank participants 
who choose to be involved, with funding provided by the 
biobank to support participant meetings. Members of this 
Participant Association would select a Participant Board, a 
group of representatives who are interested in governance 
and willing to act as a channel between biobank gover-
nors and participants. This body of elected representatives 
would meet as needed and supply members to serve on 
other biobank committees, such as ethics advisory boards, 
scientific advisory boards, data access committees, and the 
Board of Directors (23).
While these institutional mechanisms are directed at 
bringing donors into the governance process of genomic 
biobanks, the pediatric nature of the DBS collection would 
require that the parent-proxies make up the Participant As-
sociation and Participant Board.
How could a governance framework make decisions on 
the different kinds of research uses?
The inclusion of parents through a mechanism such as a 
Participants Association or a CVAB would work to broaden 
the spectrum of voices implicated in the use of DBS for 
research, still a number of questions remain unanswered. 
First and foremost, it is not clear who would – or should 
– decide what kind of governance framework would be 
in place with a DBS biobank, or who would participate in 
constructing and carrying out the work of such a frame-
work. Further, if additional bodies were added into a fu-
ture governance framework, rules would need to be es-
tablished on how the various boards and committees 
would work together (ie, would all of the boards have 
to agree on each use of DBS for research?). In the case of 
Michigan, the CVAB provided guidance to MDCH in the 
development of research guidelines for use of DBS in re-
search through the BioTrust. The BioTrust Scientific Advi-
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sory Board was implemented by MDCH to convene pan-
els to review and approve each study requesting DBS, and 
CVAB chose a member of their board to sit on the Scien-
tific Advisory Board. It is policy that this CVAB member is a 
part of every review panel approving research use of DBS. 
In whatever formulation that it may take, decisions by a 
governance framework in the future would need to tack-
le head-on the dynamics of translational research men-
tioned above and the associated role of – or need for – 
benefit sharing agreements.
THE COLLECTION AND STORAGE OF DBS
It is reasonable to think that a new retention period would 
only apply to new DBS that are collected under the new 
arrangements. In the Netherlands, existing cards could be 
used for one plus four years under the pre-existing arrange-
ments, but would need to be destroyed after five years. It 
is assumed that cards collected under old arrangements 
should not be used under the new arrangements.
To what extent – and under what circumstances – 
would communication and re-contacting be allowed?
Recently, in the Netherlands a lot has been invested in in-
forming future parents about the purpose, collection, and 
storage of DBS at different moments during pregnancy, 
and before the actual screening. Yet, more effort can be 
devoted in informing future parents via midwives and oth-
er means, such as Web sites, women’s magazines, public 
discussions, etc (24). With regards to re-contact, currently 
parents are only re-contacted if there is a positive result of 
a screen of the DBS. How therefore re-consent for further 
information for the use of DBS in research would work in 
practice (eg, for specific uses of cards for research, or for 
continued storage at the age of eighteen) is unknown.
How would informed consent for prolonged storage 
operate in practice?
Not only could the provision of informational material be 
adapted to include more on storage, management and 
use, but training of those discussing the heel prick with the 
pregnant women (in the Netherlands mostly midwives) 
need to be optimized and evaluated. In the provision of 
information on (consenting to) secondary use, the onus 
should be on safeguarding the original aim of the screen-
ing program. In addition, at the time of screening it could 
be asked whether residual material from the card could 
be used in research for a certain period, eg, until the child 
reaches the age of eighteen. This would require a different 
kind of heel prick card than the one currently used with the 
opt-out. At the age of eighteen, ethical guidelines agree a 
person should be able to re-consent (25). Having to an-
swer this question at a moment shortly after birth seems 
problematic; however, organizing a different moment in 
time might be too costly.
Where and how long could/should the DBS be kept for 
“quality control” and/or research purposes
Currently a card can be used anonymously for quality con-
trol of the screening program, for instance for optimizing 
existing test methods or develop new ones. In the Nether-
lands, an individual card can be retrieved for quality con-
trol, after asking permission from the parents, when a child 
develops a disorder after screening. It can be ascertained 
whether the test failed (was false negative) or whether the 
child acquired the disorder after birth. In case of a false 
negative further analysis may help reduce future mistakes. 
In the Netherlands, currently all cards are kept for quality 
control for one year. However, requests to retrieve the in-
dividual card may be made after a few years. Keeping the 
cards for several years (eg, three to five years) allows for 
follow-up for a longer period and increases possibilities to 
compare cases.
The question arises after what period of time other re-
search than quality control could start? The DBS samples 
should not be too old (depending on the purpose, for en-
zyme activity until three years, unless kept at -80°C, while 
DNA can still be retrieved at later stages even when stored 
at room temperature) and should be stored in appropriate 
climate conditions, which can be costly. One could already 
start using the cards for other research purposes after the 
screening, in case parents have consented. But what would 
be an optimal moment and format for asking consent (or, 
less desirable, providing an opt-out)? However, part of the 
card should be retained for quality control. If there should 
always (or for a fixed period) be enough material left for 
quality control purposes, the question is, for how long that 
could be warranted?
For quality control purposes the cards should be with or 
within control of the RIVM (currently five screening labora-
tories). It may not be necessary to actually store them with 
RIVM, in that case the DBS biobank could have a separate 
space to store the cards for quality control for a fixed pe-
riod of time (eg, one to five years), after which cards can 
be used for other purposes.
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DISCUSSION AND CONCLUSION
What we have endeavored to do here is explore some gov-
ernance questions that relate to biological materials – like 
a DBS collection – that sits sometimes awkwardly at the in-
tersection of care (ie, public health) and research. We fully 
recognize that this is not an exhaustive list of issues, yet 
at the same time similar issues will certainly play a role in 
other countries and with other bio-objects as well. Atten-
tion in the literature is being paid to these matters with 
important work being done on the regulation of hybrids in 
tissue engineering and trans-species transplantation (26), 
and even in biobank governance (27,28). If a decision were 
made to extend the period of retention for which DBS 
could be used for research purposes, then the categoriza-
tion of residual tissue left over from neo-natal screening 
would increasingly come into flux. Such a transformation 
of a DBS collection could indeed be read as a kind of bio-
objectification process wherein neonates “are first made 
into objects, [that] become possible, through scientific la-
bor and its associated technologies, and then come to be 
attributed with specific identities” (29). In the case we ex-
plored here one of those specific identities would be that 
of an institutionalized biobanking research infrastructure. 
However, as we have seen, such transformative processes 
do not come without their own sets of complications and 
challenges on how they are to be justly managed.
It is our view that three interrelated points deserve particu-
lar attention in the on-going discussion around DBS gover-
nance, which relate to its boundary crossing nature.
The first relates to the blurry lines between commercial 
and non-commercial research. While we have tried to be 
clear that a strict distinction between “public” and “private” 
may be artificial – if not misleading – in contemporary re-
search it is nevertheless a perception that may still be per-
vasive in public(s) more generally. Delineating and adjust-
ing arrangements between these kinds of research is a real 
challenge facing the governance of DBS going forward, 
as is communicating this dynamic to public(s) and DBS 
stakeholders if and when particular decisions regarding re-
search uses are made.
This problem can be exacerbated by the dynamics of 
translational medical science, and when the lines between 
what counts as a quality control use of DBS vs other kinds 
DBS research uses are unclear. What counts as quality 
control, who can do quality control, where, when, and 
for how long need to be clearly articulated in a pos-
sible future DBS biobank because the governance arrange-
ments affecting the use of DBS for research will likely differ 
from the use for quality control.
A the third and final point relates to benefit sharing agree-
ments corresponding to the fuzzy lines between the uses 
of DBS for quality control vs research by (non)commercial 
parties. The outlining of different models of benefit sharing 
is likely to be a worthwhile activity that may help to resolve 
some of the above-mentioned tensions. If for instance a 
new screen (developed either through out-right research 
or quality control work) for a new or existing condition 
on a newborn screening panel was commercialized (ei-
ther through a private entity or public-private partnership) 
then a benefit sharing agreement could allow for its not-
for-profit use in a neo-natal screening program but com-
mercial sales elsewhere. Such an arrangement could help 
to resolve the challenge of differentiating between quality 
control and research uses of DBS, as well as commercial and 
non-commercial users. Other models of benefit sharing can 
be seen in other kinds of biobanks, some including guaran-
teed access to medicines resulting from biobank-based re-
search or profit sharing from research-related products.
In general, if and when moves are made to set up a de novo 
DBS biobank it should be clear to parents when the new 
system starts and what it entails. This process needs time, 
and it is imperative that such communication is conducted 
in an understandable, balanced, and transparent manner.
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